Elucidating the role of the NLRP3 inflammasome in atherosclerosis can pave the way for the development of novel pharmacological agents aimed at modulating this pathway, thereby potentially mitigating the adverse outcomes associated with myocardial infarction and ischemic cerebral infarction [24]. This evidence concerns the gene NLRP3 and myocardial infarction.